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MEDICARE COVERAGE SOUGHT
FOR ALLO TRANSPLANTS FOR MDS
Allogeneic stem cell transplants for
myelodysplastic syndrome (MDS)
would be consistently eligible for
Medicare and Medicaid reimburse-
ment if the federal government ac-
cepts a formal request that has been
submitted by ASBMT and the National
Marrow Donor Program (NMDP), to-
gether with 10 other organizations.
‘‘We believe that the body of evi-
dence supports a coverage policy
that ensures that Medicare beneficia-
ries diagnosed with MDS have access
to allogeneic HCT,’’ said a letter asking
for a national coverage determina-
tion, submitted Sept. 21 to the Cen-
ters for Medicare and Medicaid
Services (CMS).
Medicare patients age 65 and older
represent 80% of the total population
diagnosed with MDS in the United
States. For some of these patients, al-
logeneic hematopoietic cell transplan-
tation (HCT) is the only available
curative therapy and the only treat-
ment that can prevent certain death
from the disease.
Inconsistent Coverage
Currently some Medicare regional
contractors for Part A (hospital) and
Part B (physician) services do reim-
burse for stem cell transplants for
MDS, but coverage is inconsistent
across the country. Each instance
may require extensive justification of
the efficacy of allogeneic transplants
for MDS. Without an explicit and
well-defined national policy, hospitals
often are reluctant to extend HCT ser-
vices to Medicare beneficiaries who
would benefit. A national coverage
determination would guarantee ap-
propriate and timely access to curative
treatment for MDS under the federal
health programs.
After months of gathering evidence
to document a request, ASBMT and
NMDP met with CMS representatives
in February for preliminary discussion1640about applying for a national cover-
age determination. The outcome
was encouraging enough to proceed
with assembling a coalition of organi-
zations to submit a formal request.
Those joining in the petition are:
AABB (formerly the American Asso-
ciation of Blood Banks)
American Cancer Society
American Cancer Society Cancer
Action Network
American Society for Hematology
AmericanSocietyofClinicalOncology
Aplastic Anemia and MDS Interna-
tional Foundation
Blood & Marrow Transplant Infor-
mation Network
National Bone Marrow Transplant
Link
The Bone Marrow Foundation
The Leukemia & Lymphoma Society
Several other organizations have in-
dicated that they will support the re-
quest during an expected period for
public comment.
Included in the documentation
submitted to CMS was an evidence-
base review of the scientific and med-
ical literature published in February
this year, part of the ongoing series
of comprehensive reviews of indica-
tions for HCT that ASBMT has spon-
sored and NMDP has supported over
the past 10 years. Each review is con-
ducted by a multidisciplinary panel of
experts.
Another important part of the docu-
mentation was a study conducted by
the Center for International Blood and
Marrow Transplant Research (CIBMTR)
showing that outcomes for older
adults undergoing allogeneic HCT
for MDS are not significantly different
than those of younger adults, even af-
ter adjusting for multiple risk factors.
The analysis, presented last year at
the American Society of Hematology
annual meeting, revealed no statisti-
cally significant impact of age on
transplant-related mortality, relapse,
leukemia-free survival or overallsurvival. The report has been submit-
ted for publication.
‘‘The study involved 551 MDS pa-
tients in the CIBMTR database who
were transplanted from 1995 to
2005,’’ said Claudio Anasetti, MD,
ASBMT president. ‘‘The analysis con-
cluded that age by itself should not
be a limiting factor for proceeding
with allogeneic HCT in older MDS
patients.’’
Safety and Quality
According to Michael Boo, JD, the
NMDP’s chief strategy officer, another
important element in the petition
was to show a high degree of safety
and quality for all allogeneic HCTs for
MDS and an ability to track and ana-
lyze outcomes of care for Medicare
and Medicaid patients.
‘‘For safety and quality we refer-
enced NMDP standards and the trans-
plant provider and facility standards
and accreditation of the Foundation
for the Accreditation of Cellular Ther-
apy (FACT),’’ Boo said. ‘‘For ongoing
evaluation of outcomes, we offered
the capabilities of the federally man-
dated data collection of the Stem
Cell Therapeutics Outcomes Database
(SCTOD), which is maintained by the
CIBMTR.’’
MDS becomes more common as
people age. In the United States, the
overall incidence of MDS is estimated
at 3.3 per 100,000, but the incidence
in those over 70 is between 15 and 50
per 100,000, according to recently
published epidemiological data.
CMS may seek additional informa-
tion prior to a period for public com-
ment. A decision on the request isn’t
expected until next year.STRATEGIC PLANNING SURVEY
REVEALS MEMBERS’ PRIORITIES
Research, Reimbursement and Re-
cruitment. The three words represent
top priorities of ASBMT members and
where they are looking to their soci-
ety’s leaders for effective programs.
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sponded to an online questionnaire
about the society’s programs and ac-
tivities. The strong response – about
a third of the membership – came
when the Board of Directors in May re-
quested information and opinions for
the development of the society’s next
three-year strategic plan.
The survey asked members the
open-end question ‘‘What do you
think is the greatest challenge facing
our field today?’’ The answers most
frequently given fit into the following
three categories:
 Basic and clinical research and par-
ticularly funding for research (29%)
 Reimbursement, costs and access
to care (24%)
 Workforce shortage and recruit-
ment of physicians and other clini-
cal personnel (20%)
The responding members said that
the greatest opportunities for the
BMT field are in further improvement
of therapies through continued re-
search (46%) and an expansion of
the field into other cellular therapies,
gene therapy and regenerative medi-
cine (36%).
‘‘The opinions and advice of our
members was immensely helpful
when the officers and directors met
to begin crafting a strategic plan for
the next three years,’’ said Claudio
Anasetti, MD, president. ‘‘The priorities
expressed in the survey helped guide
the deliberations of our officers and di-
rectors.
‘‘The large response from our mem-
bers speaks to the special relationship
so many have with the society, and it
added to the importance of our plan-
ning for the next several years,’’ he
said.Programs Rated
The survey respondents were given
a list of ASBMT programs and activities
and asked to indicate the importance
of each. The two that were ranked
most important were evidence-based
reviews, (chosen as ‘‘very important’’
or ‘‘important’’ by 90% of respon-
dents) and the development of clinical
guidelines (chosen as ‘‘very impor-
tant’’ or ‘‘important’’ by 88% of respon-
dents).
Other programs, ranked in de-
scending order of importance were:
Accreditation of transplant pro-
grams (FACT)
Guidelines for BMT training
Web site (www.asbmt.org)
Annual research training course for
young clinicians
Advocacy with health plans on re-
imbursement issues
New investigator awards
Legislative and regulatory relations
BMT economic studies
Travel grants to young investiga-
tors for annual meeting
Membership directory
Public awareness and education
about BMT
Monthly e-newsletter (ASBMT
eNEWS)
Contracting assistance with third-
party payers
Online CME courses and seminars
Standardized RFI (Request for Infor-
mation)
Online job opportunities (job bank)
CPT Code improvements
Overall, ASBMT programs and activ-
ities are ranked quite high. Even the
program that scored lowest – CPT
Code improvements – was rated
‘‘very important’’ or ‘‘important’’ by
62% of the respondents.Annual Meeting
Nearly 60% of those participating in
the survey said that they attended the
BMT Tandem Meetings this past Feb-
ruary in Tampa. Ninety-two percent
rated the meetings as ‘‘very good’’ or
‘‘good.’’
Asked about the balance between
clinical science and basic science,
85% percent said that the mix was
about right. Ten percent said it
skewed too much toward basic sci-
ence, and 5% said it was too heavy
in clinical science.
Among those who did not attend
the meetings, the most frequent rea-
sons were a personal schedule con-
flict (41%), not having the necessary
travel budget (22%), or having to pro-
vide patient coverage so that others
from their facility could attend (18%).
BBMT
The typical member spends be-
tween 30 and 60 minutes each
month with Biology or Blood and
Marrow Transplantation (32% of
members), while some spend more
than an hour (19% of members).
Asked to rate the journal on several
attributes, the highest score was
given to its impact on members of
the BMT field. Other highly ranked
attributes were:
Physical quality (layout, typogra-
phy, figures, use of color)
Overall reputation of the journal
Stature of editor/editorial board
Balance between basic science and
clinical research
Only Blood outscored BBMT on rel-
evance to the hematopoietic stem cell
transplant field. In terms of content
quality, BBMT was ranked just behind
Blood, New England Journal of
Medicine and Journal of Clinical
Oncology.
